Just days after Celltrion announced the Canadian launch of its Yuflyma (adalimumab) higher-strength 100mg/ml biosimilar rival to Humira, partners Jamp and Alvotech have followed suit with their Simlandi version.
The launch sets up a head-to-head battle between the two high-concentration Humira biosimilars in Canada, as Alvotech also prepares to launch its biosimilar in Europe with local partner Stada under the Hukyndra name, where Celltrion’s Yuflyma launched almost a year ago
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?